Navigation Links
American Oriental Bioengineering Honorably Elected a Top 20 Most Competitive Public Pharmaceutical Company in China

NEW YORK, July 21 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products in China, today announced that AOBO was honorably elected as one of the "Top 20 Most Competitive Public Pharmaceutical Companies in China." This event was jointly organized by China's leading healthcare industry associations, including the Chinese Pharmaceutical Enterprise Association and its publication, Healthcare Executive Magazine, and China's Center for Pharmaco-economics and Outcomes Research (CCPOR) at Beijing University, where an awards ceremony was held today.

The 20 listed companies were selected from 132 Chinese pharmaceutical companies listed in Shanghai, Shenzhen, Hong Kong, Singapore, New York or on NASDAQ, as of February of this year. The selection criteria were based on the companies' management capabilities, brand recognition, financial strength, resource accessibility and quality of key team members.

Mr. Tony Liu, Chairman and Chief Executive Officer of American Oriental Bioengineering, commented, "We are very honored to receive this recognition by the industry. This award speaks to the strength of our brand value and competitiveness in the changing environment. We will continue to focus on creating greater value for investors."

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a China-based pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products.

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended December 31, 2008, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

SOURCE American Oriental Bioengineering, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. American Mothers Seriously Concerned About Childhood Allergies, Siemens Survey Reveals
2. American Medical Informatics Association (AMIA) Submits Comments to Hit Policy Committee About Meaningful Use and Electronic Health Record Certification
3. New RISI Report Analyzes South American Tree Farm and Biomass Energy Investment Opportunities
4. Americans United for Life: Obamas Disbanding Bioethics Council Raises Troubling Questions
5. Ten Top Latin American Scientists Named 2009 Pew Fellows in the Biomedical Sciences
6. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
7. Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
8. Data for SemBioSys insulin to be presented at the American Diabetes Associations 69th Scientific Sessions
9. American Biotech Labs(R) Garners 2009 Utah Best of State Award
10. VIA Pharmaceuticals DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
11. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
Post Your Comments:
(Date:10/13/2015)... -- Research and Markets( ) has announced the ... Bone Morphogenetic Protein Growth Factor Therapy - 16 Countries ... --> --> Bone morphogenetic proteins (BMPs) ... after a fracture. In nature, these proteins have a ... the skeleton. There are twenty different BMPs that have ...
(Date:10/13/2015)... 2015 " Microbiology Culture Market - ... 2023 " , the global microbiology culture market ... reach US$7.59 bn by 2023, expanding at a CAGR of 5.9% ... " Microbiology Culture Market - Global Industry Analysis, Size, Share, ... the global microbiology culture market was valued at US$4.51 bn ...
(Date:10/13/2015)... ... October 13, 2015 , ... AxioMx ... that it has received a Phase I Small Business Innovative Research (SBIR) grant ... of General Medical Sciences (NIGMS), will fund the development of a technique to ...
(Date:10/13/2015)...      Q BioMed Inc (OTC: ... into a strategic relationship with Wombat Capital, Ltd., a ... Paris, France based strategic and scientific advisory ... This collaborative arrangement gives Q BioMed and its stakeholders ... well as long established pharmaceutical industry relationships. The advisors ...
Breaking Biology Technology:
(Date:10/5/2015)... , October 5, 2015 ... company update for NXT-ID, Inc. (NASDAQ: NXTD ), ... commerce market. --> ) ... Inc. (NASDAQ: NXTD ), a biometric authentication company ... SoundView Technology Group ( ) ...
(Date:9/30/2015)... global glucose monitoring device and diabetes management market is valued ... on the industry from Kalorama Information. Sales in the traditional glucose ... continuous glucose monitoring and sensor segment, according to the healthcare ... in its latest report, The Global Glucose Monitoring Market ... , ...
(Date:9/28/2015)... SAN FRANCISCO , September 28, 2015 ... size is expected to reach USD 12.03 billion by ... to 2020. Technological advancements such as Backside Illumination (BSI) ... revenue growth over the forecast period.      ... the back of the chip to reduce loss and, ...
Breaking Biology News(10 mins):